ArticleBMC infectious diseases2026
Heterogeneity of patient preferences for long-acting HIV treatment among people with HIV in Kenya.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
backgroundLong-acting ART (LA-ART) regimens available or in development are emerging alternatives to daily oral HIV treatment, designed to improve adherence. We explored preference heterogeneity for LA-ART among people living with HIV (PLWH) in Kenya and investigated their association with sociodemographic and psychosocial characteristics.
methodsWe designed a discrete choice experiment (DCE) to elicit preferences for LA-ART attributes among 700 PLWH recruited from three clinics in Nairobi Kenya (January 2023-February 2024). Each participant answered 17 choice-tasks, each with 2 hypothetical LA-ART alternatives and current daily oral therapy. Each LA-ART profile was defined by mode (long-acting pills, injections under the skin, injections into the muscle, and implants), pain, frequency, location of treatment, pre-treatment time undetectable, pre-treatment negative reaction testing, and late-dose leeway. Participants answered demographic and psychosocial questions and provided consent to link their clinical data. We fitted a latent-class model to the DCE data, assigned class membership to each participant, and estimated a multinomial logit model to explore associations between participant characteristics and class membership.
resultsWe found three classes in our DCE data and labeled them based on which hypothetical LA-ART formulation they preferred over their current daily oral therapy: LA-Implant (41% of the sample), LA-Injection-or-Oral (subcutaneous or intramuscular injection; 38%) and LA-Oral (21%) classes. All classes preferred "clinic" of over "home" for treatment location. Compared to LA-Oral participants, the other two classes had more experience with and less aversion to injections and had started ART more recently. LA-Implant participants were more likely to have housing insecurity. LA-Injection-or-Oral participants were less likely to be a female sex worker and to have a monthly income; and more likely to be a man who has sex with men or male sex worker, to have private insurance, and to have easier access to a clinic.
interpretationResults provide a deeper understanding of the LA-ART preference landscape. Understanding PLWH preferences for these therapies is crucial to increasing their acceptance and uptake as regimens become available and could aid in the development of preference-informed interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.